Welcome to our dedicated page for Genmab news (Ticker: GMAB), a resource for investors and traders seeking the latest updates and insights on Genmab stock.
Genmab A/S (GMAB) is a global biotechnology leader focused on creating differentiated antibody therapies for cancer and autoimmune diseases. This page serves as the definitive source for Genmab news, providing investors and industry professionals with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Access consolidated information on FDA approvals, collaboration announcements, and clinical trial results across Genmab's pipeline. The company's proprietary platforms like DuoBody and HexaBody underpin its innovative treatments, with key alliances including Johnson & Johnson and AbbVie driving therapeutic advancements.
Bookmark this page for real-time updates on Genmab's progress in antibody engineering and commercialization efforts. Monitor critical updates through verified press releases while gaining insights into how the company addresses complex medical challenges through targeted biologics.
Genmab A/S and Pfizer Inc. announced that the U.S. FDA has approved TIVDAK® for recurrent or metastatic cervical cancer treatment, converting its accelerated approval to a full approval. This is the first ADC with positive overall survival data in this patient population. The approval is based on Phase 3 data showing a 30% risk reduction in death compared to chemotherapy.
FAQ
What is the current stock price of Genmab (GMAB)?
What is the market cap of Genmab (GMAB)?
